{"title":"Elaboration and verification of immune-based diagnostic biomarker panel for diabetic foot ulcer","authors":"Hengkun Gao , Sibing Chen, Jiannan Li, Yanxi Liu","doi":"10.1016/j.jdiacomp.2025.108957","DOIUrl":"10.1016/j.jdiacomp.2025.108957","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic foot ulcer (DFU) constitutes a major complication in diabetes management. This study aimed to develop and validate an immune-related diagnostic model for DFU by identifying key genes and analyzing their functional enrichment.</div></div><div><h3>Methods</h3><div>We utilized the datasets GSE199939, GSE134431, and GSE80178 from the Gene Expression Omnibus (GEO) database. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules associated with DFU. Differentially expressed genes (DEGs) were pinpointed using the “limma” package, and functional enrichment was executed using “clusterProfiler”. A risk score for diagnosing DFU was developed using the Least Absolute Shrinkage and Selection Operator (LASSO) model. The CIBERSORT algorithm was utilized to assess immune cell infiltration. The diagnostic effectiveness of the risk score was gauged through the receiver operating characteristic (ROC) curve, and drug target prediction was performed using the DGIdb database.</div></div><div><h3>Results</h3><div>WGCNA identified a DFU-related gene module containing 2184 genes. Functional enrichment analysis revealed important pathways, including proteasome and cell cycle. Nine DEGs were recognized as immune-related candidates for DFU, predominantly involved in signaling cascades like cytokine-cytokine receptor interaction. The LASSO model selected four key genes (APOD, ULBP2, TGFBR3, TNFRSF12A) to construct a risk score, which showed high diagnostic accuracy in datasets GSE134431, GSE199939 and GSE80178 (AUC = 0.990, 1.000, and 0.926, respectively). Pronounced disparities in infiltrating immune cells were observed among DFU patient groups with disparate risk factors. Drug prediction analyses identified potential therapeutic targets for the key genes.</div></div><div><h3>Conclusion</h3><div>This study developed a powerful immune-related diagnostic model for DFU, highlighting the key genes and pathways involved in its pathogenesis. The risk score provides a valuable tool for DFU diagnosis, while the identified drug targets provide avenues for potential therapeutic intervention.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 108957"},"PeriodicalIF":2.9,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F.N.U. Sidra , Shubham Agarwal , Paola Lockhart Pastor , Donglu Xie , Xilong Li , Ildiko Lingvay
{"title":"Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy","authors":"F.N.U. Sidra , Shubham Agarwal , Paola Lockhart Pastor , Donglu Xie , Xilong Li , Ildiko Lingvay","doi":"10.1016/j.jdiacomp.2024.108925","DOIUrl":"10.1016/j.jdiacomp.2024.108925","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerotic cardiovascular disease is the leading cause of death in people with type 2 diabetes (T2D) and chronic kidney disease (CKD) or end-stage kidney disease (ESKD). Glucagon-Like Peptide-1 receptor agonists (GLP-1RA) reduce cardiovascular events, improve glycemic control, promote weight loss, and slow progression of nephropathy. Despite these benefits and professional society treatment guidelines recommendations, GLP-1RAs remain under-utilized in people with advanced CKD and ESKD due to tolerability and safety concerns.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study comparing clinical outcomes and medication use details after initiating GLP-1RA or dipeptidyl-peptidase 4 inhibitor (DPP-4i) in people with T2D and advanced CKD or ESKD. Eligible patients were identified via electronic health record query with extraction of baseline demographics, vital signs, and laboratory values. A manual chart review was undertaken to confirm eligibility, medication use, and extract a detailed account of all side effects.</div></div><div><h3>Results</h3><div>A total of 236 eligible patients (149 in the GLP-1RA group and 87 in the DPP-4i group) were identified. The average duration of treatment was 1036 (±909.9) and 1109 (±1090.9) days for GLP-1RA and DPP-4i, respectively. The average percentage weight loss from baseline to 36 months of treatment in the GLP-1RA group was −9.6 % (95 % CI, −11.3 to −7.8) versus −2.4 % (95 % CI, −5.4 to 0.5) in the DPP-4i group (estimated treatment difference (ETD) -7.1 (95 % CI, −10.6 to −3.7) percentage-points, <em>p</em> < 0.001). The change in HbA1c from baseline to 36 months of treatment was significantly greater in the GLP-1RA (−1.0 %) compared with the DPP-4i group (0.2 %) (ETD -1.2 (95 % CI, −2.1 to −0.3) percentage-points, <em>p</em> = 0.04).</div></div><div><h3>Conclusion</h3><div>In patients with T2D and advanced CKD or ESKD, treatment with GLP-1RAs in a real-world setting had long treatment persistence, and compared to DPP-4is, was associated with greater weight loss and glycemic improvement.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108925"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
So-hyeon Hong , Yongho Jee , Yeon-Ah Sung , Young Sun Hong , Do Kyeong Song , Hyein Jung , Hyejin Lee
{"title":"Impact of visit-to-visit glycated hemoglobin variability on diabetes distress and its subscales","authors":"So-hyeon Hong , Yongho Jee , Yeon-Ah Sung , Young Sun Hong , Do Kyeong Song , Hyein Jung , Hyejin Lee","doi":"10.1016/j.jdiacomp.2024.108924","DOIUrl":"10.1016/j.jdiacomp.2024.108924","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to investigate the correlations between glycated hemoglobin (HbA1C) variability and diabetes distress (DD) and its subscales in older patients with type 2 diabetes mellitus.</div></div><div><h3>Methods</h3><div>The cross-sectional study analyzed 175 patients with type 2 diabetes mellitus, aged ≥60 years, and underwent HbA1C testing at least three times within a 2-year. HbA1C variability was assessed using the coefficient of variation (CV), standard deviation (SD), variability independent of the mean (VIM), and variability score. DD was assessed using a diabetes distress scale (DDS) questionnaire. We analyzed four DDS subscales, including emotional burden (EB), regimen distress (RD), interpersonal distress (ID), and physician distress (PD). Significant DD was defined as a total score ≥ 34.</div></div><div><h3>Results</h3><div>All four indices of HbA1C variability were positively correlated with DDS (<em>r</em> = 0.19, <em>P</em> = 0.01 in CV; <em>r</em> = 0.19, <em>P</em> = 0.01 in SD; <em>r</em> = 0.19, <em>P</em> = 0.02 in VIM; and <em>r</em> = 0.18, <em>P</em> = 0.02 in variability score). For the DD subscales, only EB showed a significant correlation with HbA1C variability (<em>β</em> = 0.72, SE = 0.35 in CV; <em>β</em> = 0.70, SE = 0.35 in SD; <em>β</em> = 0.66, SE = 0.31 in VIM; and <em>β</em> = 0.77, SE = 0.35 in variability score).</div></div><div><h3>Conclusions</h3><div>HbA1C variability was independently linked to DD, particularly the EB subscale in older type 2 diabetes patients. This underscores the need for DD screening and intervention in patients with high HbA1C variability, irrespective of their HbA1C levels or depressive symptoms.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108924"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(24)00263-0","DOIUrl":"10.1016/S1056-8727(24)00263-0","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108937"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143155084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hannah Lee , Phillip J. Hartfield , Abigail Thorgerson , Grant P. Sinson , Marjorie Wang , Carlos E. Mendez
{"title":"Cambridge risk score, new hyperglycemia, and complications in surgical patients without diabetes","authors":"Hannah Lee , Phillip J. Hartfield , Abigail Thorgerson , Grant P. Sinson , Marjorie Wang , Carlos E. Mendez","doi":"10.1016/j.jdiacomp.2024.108926","DOIUrl":"10.1016/j.jdiacomp.2024.108926","url":null,"abstract":"<div><h3>Aims</h3><div>Our study examined the association between the Cambridge Risk Score (CRS), new hyperglycemia (NH), and complications in patients undergoing elective surgery.</div></div><div><h3>Methods</h3><div>In this retrospective cross-sectional study, adult surgical patients, without diabetes, with NH (blood glucose ≥140 mg/dL) were identified, and the CRS was calculated. We used univariate regression models to evaluate the relationship between CRS and NH with 30-day readmission, length of stay (LOS), and complications. Models were stratified by surgical specialty (cardiac/vascular, general, orthopedic, neurologic).</div></div><div><h3>Results</h3><div>Of 10,531 patients in the study, 24 % had NH. After adjusting for covariates, the CRS was associated with increased odds of complications [OR 2.09; 95%CI:1.69, 2.59] and NH [OR 1.95; 95%CI:1.66, 2.29]. NH was associated with increased odds of 30-day readmission [β 1.60; 95%CI:1.31, 1.96], and increased LOS [β 0.64; 95%CI:0.59, 0.68]. When stratified by surgery type, the CRS was associated with increased LOS in neurosurgery, decreased LOS in orthopedics, and increased odds of complications and NH in neurosurgery and orthopedics.</div></div><div><h3>Conclusion</h3><div>The CRS is associated with NH, complications, and LOS in patients undergoing elective neurosurgery, orthopedic surgery, and general surgery. This suggests that CRS may have potential to help identify surgical patients at high risk for NH and complications.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108926"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways","authors":"Habib Yaribeygi , Kiana Kashian , Kimia Imani Moghaddam , Sheida Rashmeh Karim , Narges Bagheri , Sercan Karav , Tannaz Jamialahmadi , Manfredi Rizzo , Amirhossein Sahebkar","doi":"10.1016/j.jdiacomp.2024.108928","DOIUrl":"10.1016/j.jdiacomp.2024.108928","url":null,"abstract":"<div><div>Patients with diabetic are at a higher risk of developing hepatic disorders compared to non-diabetic individuals. This increased risk can be attributed to the diabetic environment, which triggers and exacerbates harmful pathways involved in both diabetic complications and hepatic disorders. Therefore, it is important to consider the use of antidiabetic agents that offer benefits beyond glycemic control and have positive effects on liver tissues. Glucagon-like peptide-1 (GLP-1) mimetics are a novel class of antidiabetic medications known for their potent blood sugar-lowering effects. Emerging evidence suggests that these drugs also have favorable effects on the liver. However, the precise effects and underlying mechanisms are not yet fully understood. In this review, we aim to provide a mechanistic perspective on the liver benefits of GLP-1 mimetics and outline the mediating mechanisms involved.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108928"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Slowly progressive subtype of childhood-onset type 1 diabetes as a high-risk factor for end-stage renal disease: A cohort study in Japan","authors":"Hiroshi Yokomichi , Mie Mochizuki , Shigeru Suzuki , Yoshiya Ito , Tomoyuki Hotsubo , Nobuo Matsuura","doi":"10.1016/j.jdiacomp.2024.108922","DOIUrl":"10.1016/j.jdiacomp.2024.108922","url":null,"abstract":"<div><h3>Aim</h3><div>To compare the incidence of end-stage renal disease (ESRD) between slowly progressive type 1 diabetes and acute-onset type 1 diabetes.</div></div><div><h3>Methods</h3><div>This cohort study enrolled all 521 patients with childhood-onset type 1 diabetes with the year of onset from 1959 to 1996 in Hokkaido Prefecture, Japan. We calculated the ESRD incidence rate per 100,000 person-years by sex, onset year, onset age, and type 1 diabetes subtype (slowly progressive or acute-onset). We also constructed a Kaplan–Meier curve for ESRD by these risk factors.</div></div><div><h3>Results</h3><div>The data of 391 patients were gathered, among whom 66 developed ESRD. The ESRD incidence rate per 100,000 person-years was 525 among all patients; 538 and 503 among women (<em>n</em> = 235) and men (<em>n</em> = 156); 893, 413, and 225 for onset year of 1959–1979 (<em>n</em> = 107), 1980–1989 (<em>n</em> = 201), and 1990–1996 (<em>n</em> = 83); 420 and 715 for onset before (<em>n</em> = 243) and after (<em>n</em> = 148) puberty; and 1388 and 432 for the slowly progressive (<em>n</em> = 41) and acute-onset (<em>n</em> = 350) subtypes, respectively. The Kaplan–Meier curve also indicated a significantly higher incidence of ESRD in slowly progressive than in acute-onset type 1 diabetes.</div></div><div><h3>Conclusion</h3><div>The incidence of ESRD was higher in slowly progressive than acute-onset type 1 diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108922"},"PeriodicalIF":2.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Claudia R.L. Cardoso, Lucas da Silva Pereira, Nathalie C. Leite, Gil F. Salles
{"title":"Prognostic importance of baseline and changes in serum uric acid for macro/microvascular and mortality outcomes in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort","authors":"Claudia R.L. Cardoso, Lucas da Silva Pereira, Nathalie C. Leite, Gil F. Salles","doi":"10.1016/j.jdiacomp.2024.108921","DOIUrl":"10.1016/j.jdiacomp.2024.108921","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the associations between baseline/changes in serum uric acid (sUA) and the risks for cardiovascular/microvascular outcomes and mortality in a type 2 diabetes cohort.</div></div><div><h3>Methods</h3><div>Baseline sUA was measured in 685 individuals, and 463 had a second sUA measurement during follow-up; sUA was analyzed as a continuous variable and categorized into sex-specific tertile subgroups and low/high levels (>4.5 mg/dl women; >5.5 mg/dl men). The risks associated with baseline sUA and its changes were examined by Cox analyses for all outcomes.</div></div><div><h3>Results</h3><div>Median follow up was 10.7 years, there were 173 major cardiovascular events (MACEs), 268 all-cause deaths, 127 microalbuminuria, 104 renal failure, 160 retinopathy and 178 peripheral neuropathy outcomes. Baseline sUA was predictor of all outcomes, except all-cause mortality and retinopathy. In tertile and high/low sUA analyses, the hazard ratios (HRs) varied from 1.6 (microalbuminuria development) to 2.4 (MACEs; cardiovascular mortality). There was interaction with sex for MACEs, an increased risk was observed in women (HR: 2.6), but not in men (HR: 1.2). Changes in sUA were associated with the renal failure (HR: 2.4).</div></div><div><h3>Conclusions</h3><div>In a prospective cohort, high baseline sUA was a predictor of cardiovascular, renal and peripheral neuropathy. However, sUA changes were only predictor of renal failure.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108921"},"PeriodicalIF":2.9,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(24)00242-3","DOIUrl":"10.1016/S1056-8727(24)00242-3","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 12","pages":"Article 108916"},"PeriodicalIF":2.9,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lijiahui Lin , Siyu Zhong , Ying Zhou , Jie Xia , Shanshan Deng , Tao Jiang , Aihua Jiang , Zhimei Huang , Jianping Wang
{"title":"Dapagliflozin improves the dysfunction of human umbilical vein endothelial cells (HUVECs) by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2","authors":"Lijiahui Lin , Siyu Zhong , Ying Zhou , Jie Xia , Shanshan Deng , Tao Jiang , Aihua Jiang , Zhimei Huang , Jianping Wang","doi":"10.1016/j.jdiacomp.2024.108907","DOIUrl":"10.1016/j.jdiacomp.2024.108907","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the effect of Dapagliflozin (Da) on the disorders of human umbilical vein endothelial cells (HUVECs) induced by high glucose and high fat (HG/HF).</div></div><div><h3>Methods</h3><div>Immunohistochemistry and immunofluorescence were used to detect the SGLT-2 expression in thoracic aortic tissues. After transfected with overexpressed plasmid SLC5A2, autophagy and cell functions of HUVECs were detected with the treatment of autophagy inhibitor 3-MA (5 mM). HUVECs were exposed to mannitol (MAN), glucose/palmitate (Hg/PA), and Hg/PA/Da for 24 h, and the proliferation of HUVECs was detected by CCK-8. The protein expression levels, endothelial cell functions (cell proliferation, migration, tubular formation, apoptosis, and autophagy) in endothelial cells were evaluated.</div></div><div><h3>Results</h3><div>The SGLT-2 expression was found in atherosclerotic human thoracic aorta tissues and HG/PA induced HUVECs (<em>P</em> < 0.05). After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (<em>P</em> < 0.05). After the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (<em>P</em> < 0.05). Moreover, the increased protein expression levels of autophagy and apoptosis in HG/PA induced HUVECs were also decreased by the treatment of Dapagliflozin (<em>P</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>Dapagliflozin can improve the dysfunction of high glucose/high fat-induced human umbilical vein endothelial cells by downregulate autophagy through inhibiting SGLT-2.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108907"},"PeriodicalIF":2.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}